

Drugs – Real World Outcomes

Patients' health related quality of life and use of medicinal cannabis – a cross-sectional survey study

Authors

Frederik Rosenbæk¹, cand.scient.san.publ, frosenbaek@health.sdu.dk, +45 23611629, ORCID: 0000-0003-0214-1539, (corresponding author)

Sonja Wehberg¹, PhD, ORCID: 0000-0003-1503-2649

Line Bjørnskov Pedersen^{1,2}, PhD, ORCID: 0000-0001-6804-2045

Jesper Bo Nielsen¹, PhD, ORCID: 0000-0002-5764-5462

Jens Søndergaard¹, MD, PhD, ORCID: 0000-0002-1629-1864

¹Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.

²DaCHE – Danish Centre for Health Economics, University of Southern Denmark, Department of Public Health, Campusvej 55, 5230 Odense M, Denmark.

Comparison of QALY-scores among diagnostic indications, including mean, standard deviation, distribution of scores, and test for significance between diagnostic indications and the adult population group

Group	N	Mean (SD)	Min, p25, median, p75, max	P-value*
Multiple sclerosis	730	0.67 (0.24)	-0.29, 0.63, 0.76, 0.81, 1.00	<0.05
Paraplegia	192	0.51 (0.32)	-0.52, 0.28, 0.63, 0.76, 1.00	<0.05
Neuropathy	5999	0.74 (0.23)	-0.55, 0.70, 0.78, 0.84, 1.00	<0.05
Nausea and vomiting	509	0.81 (0.17)	0.15, 0.76, 0.83, 0.89, 1.00	<0.05
Other diagnostic indication	830	0.53 (0.27)	-0.55, 0.27, 0.63, 0.76, 1.00	<0.05
Adult general population	1061	0.87 (0.15)	-0.20, 0.81, 0.85, 1.00, 1.00	.

*Two-tailed t-test testing for significant difference from means between diagnostic indications and the adult population group.
Significance level set to $p < .05$.